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Homogeneous antibody populations from a variety of sources have proven extraor- 
dinarily useful in deducing the structure of immunoglobulin molecules. Serological 
studies of myeloma proteins, in particular, have been invaluable in delineating many 
aspects of normal immunoglobulin structure, and both myeloma proteins and induced 
antibody populations in a  variety of species have been used extensively in defining 
and  localizing  individual  antigenic  specificities  or  idiotypes  (1-4).  Subsequently, 
Williams et al. (5) and Kunkel et al. (6) demonstrated shared cross-idiotypic specific- 
ities among cold agglutinin and anti-gamma globulin antibody populations isolated 
from genetically unrelated individuals, thus suggesting a relationship betwen idiotype 
and antibody specificity. 
Amino acid sequence analysis of homogeneous antibodies has also provided inves- 
tigators with a much clearer understanding of antibody molecules, particularly with 
regard  to  structure/function  relationships.  For example,  the  domain  hypothesis of 
antibody structure was only formulated when complete primary structures could be 
compared  (7).  Compilation  of sequence data  from several  laboratories yielded the 
concept  of subgroups  (8-10)  and  hypervariable  regions  (11-13).  Affinity-labeling 
studies of purified antibodies have subsequently demonstrated that the hypervariable 
regions  are  those  portions  of the  molecule  that  make  contact  with  an  antigenic 
determinant and are responsible for antigenic specificity (14,  15). 
Efforts in our laboratories over the past  10 yr have been devoted to the serological 
and structural dissection of an induced antibody system in an attempt to understand 
its  molecular  and  genetic  implications.  All  A/J  mice,  when  immunized  with  the 
hapten p-azophenylarsonate  (Ar) 1 coupled  to  keyhole limpet  hemocyanin  (KLH), 
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make a  restricted  anti-Ar response,  20-70%  of which bears  a  cross-reactive  idiotype 
(CRI)  detected  by  an  appropriately  absorbed  rabbit  antiserum  (16).  The  CRI  is 
linked to the immunoglobulin heavy-chain locus (17), and has been one of the variable 
(V)-region markers  used  to demonstrate  linkage of variable  and constant  regions of 
immunoglobulin  heavy chains  in  mice.  Recently,  linkage  of the  CRI to the  kappa 
chain locus has been demonstrated  as well  (18,  19). 
All  structural  analyses  done  to  date  indicate  that  the  serum  anti-Ar  response  is 
extremely restricted. Thus, IgGa CRI-positive heavy chains isolated from conventional 
anti-Ar antibodies exhibit a homogeneous sequence that includes their hypervariable 
regions  (20-22).  CRI-negative heavy chains  are  homogeneous  and  identical  to  the 
CRI-positive chains with the exception of their hypervariable regions, which are quite 
heterogeneous.  CRI-positive  light  chains  appear  to  be  drawn  from  at  least  three 
different  Vk-subgroups,  but  also  have  homogeneous  and  identical  hypervariable 
region sequences  (23-25).  The CRI-negative light chains were too heterogeneous to 
sequence. 
These results suggest that the CRI-positive anti-Ar response is under strict genetic 
control and that the cross-idiotypic specificity measured serologically is comprised of 
amino acids in the hypervariable regions. 
To  further  explore  the  relationships  between  the  CRI-positive and  CRI-negative 
molecules and to verify the presumed homogeneity of the serum anti-Ar response, we 
undertook  the  generation  of monoclonal  anti-Ar  antibodies  by somatic  cell  fusion. 
Serologic analysis of the hybridoma antibodies indicates heterogeneity in their ability 
to react with a conventional anti-idiotypic reagent raised against  serum anti-Ar, and 
suggests that  each hybridoma product  may possess  in  addition  to the cross-reactive 
idiotypic determinant(s),  unique antigenic specificities  (19, 26). 2 We have previously 
reported on the amino terminal  amino acid sequences of two such monoclonal anti- 
Ar hybridomas (27, 28) and here extend those findings to an additional six molecules. 
Materials  and Methods 
Immunizations.  8- to 10-wk-old female A/J mice were immunized intraperitoneally with 0.5 
mg of Ar coupled  to  KLH  in  complete  Freund's  adjuvant  (16,  27).  Animals  were  boosted 
intravenously with antigen in saline on day 28, and spleens were removed for fusion 72 h later. 
Hybridizations.  Hybridizations were done by the method of Kennett et al.  (29) as previously 
described (27). Briefly, cells from one or two spleens  were pelleted together with  1 X  l0  T Sp2/ 
0-Agl4 cells  (30) in  the  presence  of 0.2  ml  of 30%  polyethylene glycol  1,000  (J.  T.  Baker 
Chemical  Co.,  Phillipsburg,  N.  J.)  for 6  min.  After  dilution  and  washing,  the  cells  were 
suspended in 30 ml of HY-HT medium (29) that contained  15% fetal bovine serum and were 
distributed  into microplates (Costar, Data Packaging, Cambridge, Mass.)  at  50 #1 (~1  ×  l0  s 
cells)/well.  24 h later, an additional 50 #1 of HY-HT medium that contained twice Littlefield's 
concentration of aminopterin was added to each well to make a HAT selective  medium  (31). 
Fresh HY-HAT medium (29) was added at 5-d intervals, and culture supernates were changed 
at [east twice before assaying for anti-Ar activity. 
Antisera.  Rabbit anti-mouse immunoglobulin, A/J anti-Ar, rabbit anti-CRI, and goat anti- 
rabbit  Fc were  prepared  as  previously described  (16,  32).  Anti-idiotypic antiserum  against 
HP93G7 was prepared  in a  rabbit  by injections of specifically purified  hybridoma product. 
The antiserum was adsorbed by passage over two columns of Sepharose 4B (Pharmacia Fine 
Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) to which a crude fraction of normal A/ 
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J  globulins had been conjugated by using cyanogen bromide (33). Subclass-specific rabbit anti- 
mouse immunoglobulin reagents absorbed for cross-reacting specificities  were purchased from 
Litton Bionetics Laboratory Products (Kensington, Md.) for Ouchterlony analyses. 
Assays.  Culture supernates were assayed for anti-Ar activity by a solid-phase radioimmu- 
noassay with  polyvinyl Cooke  microtiter  plates  (Cooke  Engineering  Co.,  Alexandria,  Va.) 
coated with bovine serum albumin-Ar as previously described (26, 27). Anti-Ar antibodies were 
detected with t2SI-labeled rabbit anti-mouse immunoglobulin. A competition assay for the CR! 
was carried out as previously described (16) with 10 ng of specifically purified a25I-labeled serum 
anti-Ar, rabbit anti-CRI, goat anti-rabbit  Fc, and various unlabeled inhibitors,  including Ar 
binding  culture  supernates  and  A/J  serum  anti-Ar.  4  of  19  anti-Ar  isolates  were  positive 
for  the  CRI.  A  second  competition  assay  was  carried  out  with  10  ng  of  radiolabeled 
purified HP93G7, adsorbed rabbit anti-idiotype against hybridoma product (HP)93G7 [anti- 
id(93G7)], goat anti-rabbit Fc, and unlabeled inhibitors. 
Isolation ofMonoclonal Anti-Ar Antibodies.  Anti-Ar-producing hybridoma cells were grown to 
mass culture, and aliquots were stored in liquid nitrogen. Cells from each line were injected 
intraperitoneally into Pristane-primed CAF1 mice at 5 ×  106 cells/mouse.  10-14 d later, ascites 
fluids  were  drained,  and  anti-Ar  antibodies  were  purified  on  a  column of human  gamma 
globulin-Ar coupled to Sepharose 4B (32, 33). Bound material was eluted with 0.2 M arsanilate, 
dialyzed exhaustively against Tris-buffered saline  (pH 8.2),  then against distilled  water, and 
lyophilized. 
Sequencing Methods.  Purified anti-Ar antibodies were completely reduced and alkylated in 5 
M  guanidine HC1/0.5 M  Tris  (pH 8.2).  Heavy and light chains were separated  in the same 
buffer on a  Ultrogel  AcA34 column,  1 ×  100 cm.  Each peak was pooled,  dialyzed against 
distilled  water, and lyophilized. Chains were assessed  for purity by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis according to Laemmli  (34). Because the hybridomas were 
generated by fusion with a nonsecreting cell line, no further separations were necessary. Amino 
terminal  sequence  analysis  was  performed  on  the  intact  individual  chains  as  previously 
described  with  a  Beckman automated  sequencer  (model  890C,  Beckman  Instruments,  Inc., 
Spinco Div., Palo Alto, Calif.)  (20, 22-25, 35). Phenylthiohydantoin (PTH) amino acids were 
identified with high-pressure liquid chromatography, gas chromatography, and back hydrolysis 
with subsequent amino acid analysis. 
Results 
Production and Characterization of Anti-Ar-producing Hybridomas.  The eight monoclonal 
anti-Ar  antibodies  subjected  to amino  terminal  amino  acid sequence  analysis  were 
generated in two separate fusion experiments.  In the first experiment, 21 of 54 hybrids 
were positive  for anti-Ar activity.  Because  the  frequency of positive wells was high, 
HP93G7, HP91A3, HP92D5, and HP94B 10 were cloned by limiting dilution to insure 
their  monoclonality.  In  the  second  experiment,  only  39  of 268  potentially  positive 
hybrids  exhibited  anti-Ar  activity.  Because  the  frequency of anti-Ar-positive  hybri- 
domas  in  this  experiment  was only  15%,  the cells  were not cloned;  and  four of the 
hybrids,  HP121D7,  HP123E6,  HP124El,  and  HP123E4  were  chosen  for  further 
study. Sequence analyses indicate that in terms of the anti-Ar-producing population 
of cells,  the  hybrids  are  monoclonal.  With  respect  to other  parameters,  the  hybrid 
cells  may be heterogeneous,  and  each culture  may contain  cells  derived  from more 
than one fusion event. This should not interfere with studies performed on an isolated, 
specific product. 
Supernates from the eight cell lines, as well as purified anti-Ar antibody from CAFx 
ascites,  were tested  for their  ability  to inhibit  the binding of radiolabeled,  purified, 
CRI-positive antibodies  from A/J mice to the rabbit  anti-CRI reagent.  As indicated 
in Table I, four of the hybridoma products effectively inhibit  the binding of the 125I- 
labeled CRI-positive antibodies by 50%, although marked quantitative  differences in 866  STRUCTURAL STUDIES ON  INDUCED ANTIBODIES 
TABLE  I 
Displacement of Labeled A/J Anti-At from Its Rabbit Anti-ldiotypic 
Antibodies By Unlabeled A/J Anti-At Antibodies or Hybridoma Products with 
Anti-At Activity * 
Unlabeled inhibitor  Nanograms required  Percent inhibition 
for 50% inhibition  by 2 #g 
ng  % 
Serum anti-Ar  11  97 
H P93G 7  12  90 
HP121D7  300  71 
HP 123E6  1,900  51 
HP124E1  2,900  47 
HP91A3  ~:  4 
HP123E4  ~  2 
HP94B 10  ~  0 
HP92D5  :~  4 
* Each  assay  used  10  ng  of 125I-labeled, specifically  purified  A/J  anti-Ar 
antibodies and slightly  less than an equivalent amount of anti-idiotype. 
:~ 50% inhibition never achieved. 
TABLE  II 
Displacement of Labeled HP93G7  from Its Autologous Anti-Idiotypic 
Antibodies By Unlabeled A/J Anti-At Antibodies or Hybridoma Products with 
Anti-Ar Activity * 
Unlabeled inhibitor  Nanograms required  Percent inhibition 
for 50% inhibition  by 2/tg 
ng  % 
Serum anti-Ar  1,600  55 
HP93G7  80  97 
HP121D7  >2,000  19 
H P 123E6  >2,000  14 
HPI24EI  >2,000  15 
HP91A3  :~  7 
* Each  assay  used  10  ng of 12'~I-[abeled, specifically  purified  HP93G7  and 
slightly  less than an equivalent amount of anti-id(93G7). 
50% inhibition never achieved. 
their ability to do so are evident.  One  hybridoma  product,  HP93G7,  appears  almost 
as  effective  as  serum  anti-Ar  as  an  inhibitor  of  the  CRI/anti-CRI  reaction.  The 
remaining  four  anti-Ar  antibodies  are  unable  to  inhibit  the  reaction  at  all,  even  in 
very large amounts.  By Ouchterlony  analysis, all eight hybridoma  products  are of the 
IgG1 subclass. 
The  ability  of the  four  CRI-positive  hybridoma  products,  one  CRI-negative  hy- 
bridoma product,  and A/J  serum anti-Ar to inhibit the reaction between radiolabeled 
specifically  purified  HP93G7  and  its  autologous  anti-idiotype  is shown  in  Table  II. 
The  failure  of a  very  large  amount,  2,000  ng,  of each  of  the  other  CRI-positive 
hybridoma  products  to  cause  50%  inhibition  of  the  binding  of  anti-id(93G7)  to 
HP93G7  indicates  that  all  of  the  idiotypic  determinants  of protein  93G7  are  not 
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GLU VAL  GLN  LEU  GLN GLN  SER  GLY ALA  GLU  LEO  VAL  LYS ALA  GLY  SER  SER  VAL  LYS MET  SER  CYS  LYS ALA  THR  GLY TYR THR  PHE  SER 
SER  THR 
124E1  ARG  THR 
123E6  THR  SER  THR  SER  SER 
THR 
CRI- HP 
91A3  GLY, 
123E4  ARG  GLU  SER~LYS 
94BI0  ASP  GLU  PRO GLY__PRO  SER  GLN__LEU SER  LEU  THR__THR VAL.  SER  ILE  THR 
92D5  ASP  GLU  PRO GLY  PRO  SER  GLN__LEU SER  LEU  THR__THR VAL  SER  ILE  THR 
FIG.  1.  Anti-Ar hybridoma heavy chains. Comparison of the amino acid sequences of the CRI- 
positive and  CRI-negative  hybridoma  heavy-chain-variable  regions  with  the  sequence  of CRI- 
positive heavy chains found in serum. Identical residues are indicated by a line and only differences 
are noted. 
CRI+ SERUM 
10  2O 
ASP  ILE  GLN  MET  THR  GLN  THR  PRO  SER  SER  LEU  SER  ALA  SER  LEU  GLY  ASP  ARG  VAL  SER  ILE  SER  CYS  ARG  ALA  SER  GLN 
VAL  ILE  LEU  LEU 
CRI+ HP 
93G7  ,THR 
1ZID7  THR 
124E1  THR  THR 
123E6  SER  THR  THR 





Fxo.  2. 
THR  GLU~GLY 
THR 
~VAL~ILE  SER  TYR__ALA__THR PRO~GLU__ILE  THR__THR 
__VAL  VAL  LEU  THR  VAL  THR  ILE__GLN PRO  ALA  LYS 
Anti-Ar hybridoma light chains. Comparison of the amino acid sequences of the CRI- 
positive and CRI-negative hybridoma light chains with the sequence of CRI-positive light chains 
found in serum. Identical residues are indicated by a line and only differences  are noted. The major 
framework sequence of pooled antibody is listed on top with the minor sequence noted below for 
positions 3, 10, 12, and 22. 
Ar antibodies were capable of causing 50% inhibition, a  very large amount, 1,600 ng, 
was required. Thus, one or more idiotypic determinants of HP93G7 are present only 
at a  very low concentration, or are absent, from the pooled serum antibodies. 
Ammo  Terminal Amino Acid Sequence Analysis.  Eight monoclonal anti-Ar antibodies 
were selected for amino acid sequence analysis. Four of these molecules bear the A/J 
anti-Ar CRI as defined by their ability to inhibit by at least 50% the reaction between 
serum or ascites CRI-positive molecules and a  rabbit anti-CRI reagent. The other 
four molecules are  negative for the  idiotype.  Isolated heavy and light  chains from 
each  of the  eight  molecules were  subjected  to  automated  sequence analysis. Each 
PTH  amino acid  was  subjected  to  three  analytical procedures,  and  unambiguous 
assignments could be made at every position. The results are shown in Figs.  1 and 2, 868  STRUCTURAL STUDIES ON INDUCED ANTIBODIES 
where  the  first  framework  segments  are  compared  with  the  previously  reported 
structures of anti-Ar heavy and light chains isolated from hyperimmunized A/J mice. 
Discussion 
The amino terminal  framework sequences of eight  individual  anti-Ar antibodies 
obtained  by  somatic-cell  fusion  of A/J  spleen  cells  with  a  nonimmunoglobulin- 
secreting tumor-cell line have been analyzed. The 16 chains (8 heavy and 8 light) of 
these hybridoma antibodies are compared with the previously sequenced heavy and 
light chains of anti-Ar antibodies isolated from hyperimmunized A/J mice (20, 22- 
25, 35). In the previous studies, the only detectable sequence differences between anti- 
Ar antibodies with and without the CRI lay within the hypervariable regions of the 
heavy chains (CRI-negative light chains were too heterogeneous to sequence). Except 
in mice suppressed for the CRI, CRI-positive and CRI-negative heavy chains gave a 
homogeneous and identical framework sequence. In addition, the heavy- and light- 
chain hypervariable regions of CRI-positive antibodies were homogeneous, whereas 
those  of CRI-negative  antibodies  were  very heterogeneous.  The  slight  framework 
heterogeneity found in CRI-positive light chains was attributable to the presence of 
at least three different framework structures associated with identical hypervariable 
regions  (23-25).  Because  the  only  detectable  structural  difference between  CRI- 
positive and CRI-negative anti-Ar antibodies lay within  the hypervariable regions, 
and these two types of molecules were known to differ serologically with respect to a 
CRI, it was of interest to us to further investigate the possible structural relationships 
between them. 
CRI-Positive Anti-At Hybridoma Heavy Chains Are Similar but Not Identical to CRI-Positive 
Anti-Ar Heavy Chains Isolated  from Serum or Ascites.  Four different CRI-positive anti-Ar 
hybridoma heavy chains have been sequenced, and the first 30 residues are compared 
in  Fig.  1  to  the  CRI-positive  heavy-chain  sequence  previously  reported  (20,  22). 
Whereas antibodies isolated from hyperimmune A/J serum consistently gave a nearly 
homogeneous sequence (20, 21), clear differences from this sequence exist in the heavy 
chains of the hybridoma antibodies. With the exception of the Lys-Ser interchange at 
position  13 in HP123E6, all the CRI-positive heavy-chain substitutions could have 
arisen from a single base change in the DNA encoding the major (serum) sequence. 
CRI-Negative  Anti-Ar Heavy  Chains  May Either  Be  Very Similar  to  CRI-Positive  Heavy 
Chains or Be Completely Different.  The four CRI-negative heavy chains can be divided 
into two groups according to their amino terminal framework sequences (Fig. 1). Two 
of the molecules, HP91A3 and HP123E4, are clearly as related to the serum heavy- 
chain sequence as are the CRI-positive hybridoma heavy chains. That is, they belong 
to the Vnn-subgroup of mouse immunogtobulin heavy chains  (20).  Again, however, 
definite differences from the serum sequence are noted in each of the chains. As with 
the  CRI-positive chains,  substitutions  are  found at  several  different positions,  but 
appear to be more random with respect to the variant amino acid. 
In sharp contrast to the serum-like sequences are two anti-Ar, CRI-negative heavy 
chains that bear no resemblance to any of the A/J anti-Ar molecules thus far reported 
(20,  21,  35,  36).  Comparison  with  all  mouse  heavy chains  reported  to  date  (37) 
indicates that they are most like the MOPC-315 heavy chain (38).  Several points are 
worth noting wittl respect to these unusual chains. First, the two chains are identical 
to position 30.  Second, because the light-chain sequences (see below and Fig.  2)  are P.  ESTESS, E.  LAMOYI, A.  NISONOFF, AND J.  D.  CAPRA  869 
entirely different, the two hybridoma products arose independently  and,  thus,  may 
reflect a  germ-line heavy-chain sequence.  Third,  MOPC-315  is an IgA myeloma of 
BALB/c origin (39), and the finding of a strikingly similar variable region in a heavy 
chain from an A/J mouse may indicate a sharing of VH repertoires between the two 
mouse strains. 
Variability  in  Anti-Ar  Hybridoma Light  Chains Parallels  That  Found  in  the  Heavy 
Chains.  The sequences of both CRI-positive and CRI-negative anti-Ar hybridoma 
light chains  are illustrated  in  Fig.  2,  along with the sequences  found  in serum A/J 
anti-Ar antibodies that are positive for the CRI. Several striking features are apparent. 
First, with respect to the Vk-subgroup, the hybridoma molecules are more restricted 
than  the CRI-positive molecules in A/J serum.  Although  only one heavy-chain V- 
region  subgroup  is  present  in  the  serum  CRI-positive  molecules,  it  is  found  in 
association with at least three different light-chain V-region subgroups (23-25). Six of 
the eight hybridoma light chains (four with the CRI and two without)  clearly belong 
to  the  same  Vk-subgroup  as  the  major  population  of serum  anti-Ar  light  chains, 
whereas none belong to the two other subgroups. As in the monoclonal heavy chains, 
amino acid substitutions are found in the framework portions of all of the hybridoma 
light chains. Whereas the framework substitutions are not as extensive as those found 
in the heavy chains, a preponderance of Ser and Thr is again apparent. 
Perhaps the most striking observation is the Ser-Thr interchange at position 20 in 
all six of the light chains that belong to this subgroup. It must be emphasized that the 
sequence  previously  reported  for  the  CRI-positive  light  chain  was  derived  from 
antibodies isolated from a single mouse (25). When pools of CRI-positive anti-At light 
chains  from several mice were analyzed,  Set  and  Thr were equally  represented  at 
position 20 (23).  It was only in the individual animal that the major (80%)  residue at 
this  position  was  a  Ser.  Therefore,  whereas  it  is  not  unexpected  to  find  a  Thr  at 
position  20  in  anti-At  light  chains,  it  is  somewhat  surprising  to  find  it  in  all  six 
hybridoma  chains.  A  survey  of all  mouse  kappa  light  chains  sequenced  to  date 
indicates that all have either a  Ser or a Thr at position 20, with Thr being by far the 
more common (70%). There are several possible interpretations for these findings. One 
is that all Vk germ-line genes encode a Thr (or Ser) at position 20 and that there is a 
directed  (programmed) somatic alteration to (but only to) the alternate form. Thus, 
most kappa light chains will have a Thr, whereas all others a Ser. Another possibility 
is that the hybridoma and serum anti-Ar light chains reflect the existence of another 
germ-line gene that is extremely similar but not identical  to that which encodes the 
major CRI-positive light-chain-variable  region.  This  then  would  be a  fourth  light- 
chain  framework associated  with  this  cross-idiotypic  specificity in  addition  to  the 
three previously reported (25). 
A similar situation is seen at positions 7 and 8 in two of the CRI-positive hybridoma 
light  chains.  Again,  when  anti-Ar  light  chains  isolated  from pooled  material  were 
analyzed,  Ser was found at  the  15% level in position  7 and Thr at the 60% level in 
position 8. However, in chains from a single mouse, no Ser was found, and only 15% 
Thr.  If each of these  additional  differences reflects additional  germ-line  genes,  the 
number of light chains associated with CRI must be increased again. Unlike most of 
the substitutions found in the heavy chain, the light-chain framework differences are 
clearly  not  random,  as  each  one  is  present  to  some  extent  in  the  serum  anti-Ar 
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In contrast  to the CRI-negative serum antibodies,  which  are extremely heteroge- 
neous, two of the CRI-negative hybridoma light chains appear to be drawn from the 
same repertoire as the CRI-positive chains. The substitutions  at positions 25 and 27 
in  HP91A3  may  represent  the  beginning  of  the  first  hypervariable  region.  The 
HP92D5  and  HP94B10  light  chains,  like  their  corresponding  heavy  chains,  are 
strikingly different from the other six light chains and from each other as well. Neither 
chain bears any resemblance to A/J anti-Ar light chains. In particular, neither chain 
has anything in common with the MOPC-315 light chains. Their origin and relevance 
are unknown. 
Implications of the Amino  Terminal Amino  Acid Sequence Analysis  of Anti-Ar Hybridoma 
Antibodies.  In  light  of the  work  that  has  been  done  on  the  arsonate  system,  these 
results have important implications with regard to our thinking on what constitutes 
an idiotypically homogeneous antibody population as well as on the general concept 
of idiotypic  inheritance.  It  is  clear that,  in  the absence of trivial explanations,  the 
CRI-positive anti-Ar  antibody  population  in  the  A/J  mouse,  although  appearing 
homogeneous  when  serum  or  ascites  are  analyzed,  is  not.  To  some  extent,  the 
microheterogeneity  found  in  the  hybridoma  chains  is  not  inconsistent  with  the 
previously reported sequences. Thus, the substitutions at positions 7, 8, and 20 in the 
light chains and positions 16 and 25 in the heavy chains can be found in pools of anti- 
Ar antibodies derived from several animals (20, 23).  It is interesting to note that the 
Ser at position 25 in the heavy chain of the CRI-positive hybridoma product HP 123E6 
was only seen in the CRI-negative serum pool (20). The other substitutions found in 
the hybridoma heavy chains, however, have never been detected in either serum or 
ascites pools. As repeatedly stressed previously (20,  22-25),  it is important  to realize 
that sequencing methodology cannot detect variations of <5%. It may well be that if 
100  such  monoclonal  antibodies  were  sequenced,  one  might  find  some  degree  of 
variation  at  virtually  every  position.  How  such  molecules  might  arise  and  their 
relationship to one another can only be speculated upon. It does not seem unreasonable 
to hypothesize that, at least for the CRI-positive molecules, each derives from one or 
a  few  germ-line  genes  and  that  somatic  mutation  can  and  does  operate  on  the 
framework portions of antibody molecules. This is  in contrast  to the situation  with 
the  variable regions of mouse myeloma lambda chains,  where  differences from the 
supposed germ-line sequence are found exclusively in the hypervariable regions (40). 
Another possibility is that each of the hybridoma chains reflects a  different germ- 
line gene. If so, there are at least two possibilities that might explain why they were 
not detected in earlier sequencing studies. As already mentioned, each gene product 
may  be  present  at  too  low  a  level  to  detect;  but,  with  differences  as  slight  and 
apparently random as many of those seen here, could result in an overall homogeneous 
appearance. Second, it may be that whereas such minor clones exist in the A/J mouse, 
their expression is regulated against. When spleen cells are subjected to somatic-cell 
fusion,  it  may be that  such  nonexpressed  clonal  precursors  are  rescued  from  their 
regulatory environment. At this time, there is no way to discriminate between somatic 
vs.  germ-line origins, although  the situation  with the light-chain sequences suggests 
the presence of multiple germ-line genes. 
Table I indicates that whereas four of the hybridorna anti-Ar antibodies can inhibit 
the CRI/anti-CRI reaction, they do not do so to the same extent. This is reminiscent 
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glutamic acid, alanine, and tyrosine (GAT) antibodies, each of which express only a 
fraction of the common  (C)GAT idiotypic specificities as well as having individual 
idiotypic specificities. A fundamental difference between the two systems, however, is 
the  ability in  the  arsonate system of several monoclonal  antibodies  to cause >90% 
inhibition  of the reaction between CRI and anti-CRI  (19). 2 None of the anti-GAT 
antibodies could inhibit serum anti-GAT >60%, probably because of the presence of 
at  least  two  sets  of idiotypic  specificities  in  the  serum  antibody.  Because  of the 
monoclonality  of the  HP93G7  molecules,  their  ability  to  inhibit  serum  CRI  90% 
suggests that nearly all of the idiotypic determinants  detectable by the rabbit anti- 
CRI  can  exist  on  a  single  molecule.  One  explanation  then  for  the  quantitative 
differences  between  the  hybridoma  products  in  the  inhibition  assay  is  that  each 
monoclonal antibody only possesses a portion of the cross-reactive determinant (s), i.e., 
some,  but  not  all,  of  the  CRI-associated  hypervariable  regions.  This  would  be 
consistent with the concomitant finding, indicated in Table II, that HP93G7 possesses 
additional idiotypic determinants not shared by any other hybridoma product tested 
thus  far, and present  at only very low levels, if at  all,  in serum anti-Ar antibodies. 
Data obtained with anti-idiotypic antisera raised against other CRI-positive anti-Ar 
hybridoma products  indicate  that  many possess such  individual  antigenic  determi- 
nants  and  that  there  is  considerable  serological as well  as  structural  heterogeneity 
within the anti-Ar antibody population when analyzed at the monoclonal level (19). 2 
In addition,  data  to be published  elsewhere  (19) 2 have demonstrated  that  the CRI 
may be associated with immunoglobulins of any class or subclass. In the case of CRI- 
positive anti-Ar antibodies found in induced A/J ascites, a large proportion of CRI- 
positive molecules are of the IgGa subclass, and the IgG1 population can be purified 
by isoelectric focusing (33). 2 
The finding of both shared and unique idiotypic determinants amongst monoclonal 
anti-Ar antibodies,  combined with  probable first  hypervariable region  identity  be- 
tween CRI-positive serum A/J antibodies and many hybridoma products (data not 
shown)  plus  the  possibility  of  several  heavy-  and  light-chain  frameworks  being 
associated with idiotype-positive molecules suggests very strongly that either the germ- 
line  anti-Ar  repertoire  is  far  greater  than  previously  imagined  or  that  somatic 
rearrangements  have  occurred  yielding  molecules  with  some,  but  not  all,  of  the 
characteristics  of the  major CRI-positive molecules.  Whether  such  rearrangements 
might  occur  by  gene  interaction  (42),  via  more  massive DNA  rearrangements  or 
posttranscriptionally, can only be speculated on at this time. Experiments are currently 
in progress to analyze the complete V-region structures of several of these molecules 
to probe the extent of the framework variation and perhaps answer these questions. 
It might be argued that the amino acid substitutions in the framework segments of 
monoclonal anti-Ar antibodies are an artifact of the hybridoma system. The issue of 
somatic mutants arising in culture  is one of concern,  although  it can tentatively be 
ruled out by some preliminary results.  First,  sequence analysis of material passaged 
continually in CAF1 mice and isolated 6 mo apart has given identical results. Second, 
repeated cloning and resequencing of myeloma proteins in the absence of any kind of 
selection  for variants  has  not  indicated  that  such  mutants  arise  to  any detectable 
extent  (B.  Birshtein.  Personal  communication.).  It  is  important  to  note  that  such 
mutations probably do occur, but that  in the absence of any selective advantage in 
culture, it is unlikely that such a mutant would become the dominant population. It 872  STRUCTURAL STUDIES ON  INDUCED ANTIBODIES 
cannot  be  formally  excluded  that  such  a  somatic  event  took  place  immediately 
subsequent  to the  fusion event at  the one- or two-cell stage.  These possibilities can 
and are being tested by recloning and resequencing of several independent clones. 
A final point of interest concerns the two extremely unusual CRI-negative hybrid- 
oma  products,  HP92D5  and  HP94B10.  These  two  antibody  molecules  bear  little 
resemblance to any of the induced A/J anti-Ar antibodies or to that population that 
arises when A/J mice are suppressed for the CRI (20-22,  35). Their origin in the A/ 
J  repertoire is unclear, although the heavy chains resemble those of the dinitrophenyl 
binding  BALB/c  myeloma  MOPC-315.  It  may  be  that  these  two  molecules  are 
products of anti-Ar clones that are normally suppressed in A/J mice and that  have 
been rescued by fusion. 
In conclusion, it seems clear that the CRI-positive A/J anti-Ar antibodies that have 
appeared to be a restricted population by both the criteria of idiotypic cross-reactivity 
and amino acid sequence analysis may be, in fact, very heterogeneous. The extent of 
this microheterogeneity and its implications for the origins of antibody diversity are 
being explored by additional sequencing studies combined with serological analysis of 
the individual  and cross-reacting idiotypic determinants on the monoclonal anti-Ar 
antibodies. These studies should  lead to the precise chemical definition  of both the 
CRI and the individual antigenic specificities associated with these molecules. 
Summary 
Amino terminal amino acid sequence analyses have been performed on the heavy 
and light chains of induced monoclonal antibodies with specificity for the hapten p- 
azophenylarsonate.  Four of the eight  antibodies react with conventional  antisera to 
the previously described  A/J anti-arsonate cross-reactive idiotype  (CRI). Of the  16 
chains  analyzed,  all  but  one contain  sequence  differences in  their  first  framework 
segment  (residues  1-30)  that  distinguish  them  from  the  heavy-  and  light-chain 
sequences found in anti-arsonate antibodies isolated from A/J serum or ascites fluid. 
The presence of such framework differences appears to be independent of whether or 
not the hybridoma antibodies bear the CRI. In spite of the framework substitutions, 
all  four of the CRI-positive hybridoma antibodies  have variable  (V)-region  frame- 
works that are very similar to each other and to the CRI-positive molecules found in 
A/J serum. Two of the four CRI-negative molecules are also structurally similar to 
the serum antibodies. Two others, however, are strikingly different  from any serum 
anti-arsonate antibody thus far described and appear to reflect a completely separate 
repertoire  of anti-arsonate  antibodies  in  the  A/J  mouse.  In  addition,  serological 
analyses with an anti-idiotypic antiserum generated against a CRI-positive hybridoma 
product  suggest  that  each  monoclonal  antibody  may  possess  individual  antigenic 
specificities different from the determinant(s)  detected with the conventional rabbit 
anti-CRI.  The consistent  appearance of framework substitutions  in  what  has been 
thought  to be a  homogeneous antibody population  has important  implications  for 
our understanding of the generation of antibody diversity and for the precise chemical 
definition of an idiotype. 
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